Patent ID: 8304408

Claim:
A method for abrogating self-renewal of a leukemia cancer stem cell comprising: (a) providing: a pharmaceutical composition comprising a compound having a formula: and wherein X is selected from the group consisting of NH, O, S and CH 2 , and R 1 and/or the R 2 group are independently selected from the group consisting of a hydrogen, a halo, a hydroxy, a mercapto, a cyano, a formyl, an alkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, a haloalkyl, an alkenyl, an alkynyl, an aryl, a substituted alkyl, alkenyl or alkynyl, an amino, a nitro, an alkoxy, a haloalkoxy, a thioalkoxy, an alkanoyl, a haloalkanoyl and a carboxy, wherein the “hetero” term refers to groups that contain one or more heteroatoms selected from the group consisting of O, S, N and combinations thereof, and, a pharmaceutically acceptable carrier; and (b) administering the pharmaceutical composition to a subject in need thereof.